CN102356081B - 减少β-淀粉状蛋白生成的双环化合物 - Google Patents

减少β-淀粉状蛋白生成的双环化合物 Download PDF

Info

Publication number
CN102356081B
CN102356081B CN201080012637.2A CN201080012637A CN102356081B CN 102356081 B CN102356081 B CN 102356081B CN 201080012637 A CN201080012637 A CN 201080012637A CN 102356081 B CN102356081 B CN 102356081B
Authority
CN
China
Prior art keywords
phenyl
azepine
triazolo
amine
tetrahydrochysene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080012637.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102356081A (zh
Inventor
L·R·马钦
L·A·汤普森三世
K·M·博伊
J·M·盖尔农
M·A·希金斯
施建良
邬永金
张云惠
J·E·马科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102356081A publication Critical patent/CN102356081A/zh
Application granted granted Critical
Publication of CN102356081B publication Critical patent/CN102356081B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
CN201080012637.2A 2009-01-16 2010-01-12 减少β-淀粉状蛋白生成的双环化合物 Expired - Fee Related CN102356081B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14531909P 2009-01-16 2009-01-16
US61/145319 2009-01-16
PCT/US2010/020710 WO2010083141A1 (en) 2009-01-16 2010-01-12 Bicyclic compounds for the reduction of beta-amyloid production

Publications (2)

Publication Number Publication Date
CN102356081A CN102356081A (zh) 2012-02-15
CN102356081B true CN102356081B (zh) 2014-08-27

Family

ID=42061022

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080012637.2A Expired - Fee Related CN102356081B (zh) 2009-01-16 2010-01-12 减少β-淀粉状蛋白生成的双环化合物

Country Status (8)

Country Link
US (1) US8349880B2 (https=)
EP (1) EP2379553B1 (https=)
JP (1) JP5638007B2 (https=)
CN (1) CN102356081B (https=)
AR (1) AR075139A1 (https=)
ES (1) ES2426023T3 (https=)
TW (1) TW201030002A (https=)
WO (1) WO2010083141A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
BRPI1011190A8 (pt) 2009-05-07 2016-11-16 Janssen Pharmaceuticals Inc Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
EP2523949B1 (en) * 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
US9150591B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
KR20130139895A (ko) 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸
TW201309655A (zh) * 2011-01-28 2013-03-01 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
CA2830027C (en) 2011-03-31 2016-04-26 Pfizer Inc. Novel bicyclic pyridinones
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
NZ702611A (en) 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
EP2687528A1 (en) 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es) 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
WO2014127816A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
NO3004079T3 (https=) 2013-06-04 2018-06-16
US9611254B2 (en) 2013-06-04 2017-04-04 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
DK3004080T3 (da) 2013-06-04 2019-01-02 Acturum Real Estate Ab Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN109311878B (zh) * 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3535266B1 (en) * 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Bicyclic heteroaryl derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
EP3728262B1 (en) 2017-12-18 2023-03-15 F. Hoffmann-La Roche AG Triazolo-azepine derivatives
CN111417636B (zh) * 2018-01-22 2023-09-26 豪夫迈·罗氏有限公司 三唑并-氮杂䓬衍生物
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
CN114787163A (zh) 2019-11-29 2022-07-22 豪夫迈·罗氏有限公司 用于制备 (9S)-2-溴-9-(2,3,4-三氟苯基)-6,7,8,9-四氢-5H-[1,2,4]三唑并[1,5-a]氮杂䓬的方法
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途
US20260049071A1 (en) * 2022-08-08 2026-02-19 Beyang Therapeutics Co., Ltd. Protein tyrosine kinase inhibitor and medical use thereof
CN120324393B (zh) * 2025-05-20 2025-11-04 广东海洋大学 (2,4-二氯苯基)甲基硫基甲烷脒及其盐的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059955A1 (es) * 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
RU2009144998A (ru) * 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
KR101138045B1 (ko) 2007-05-11 2012-04-24 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제로서의 헤트아릴아닐린
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
BRPI0815773A2 (pt) 2007-08-31 2019-09-24 Eisai R&D Man Co Ltd composto, e, medicamento.
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
JP5328816B2 (ja) 2008-02-22 2013-10-30 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
β-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer′s Disease;D.A. Butterfield 等;《Biochemical and Biophysical Research Communications》;19940430;第200卷(第2期);第710-715页 *
人参皂苷Rbl抑制p淀粉样蛋白笛塔诱导的皮层神经元tau蛋白过度磷酸化;曾育琦 等;《药学学报》;20050630;第40卷(第3期);第225-230页 *

Also Published As

Publication number Publication date
TW201030002A (en) 2010-08-16
EP2379553B1 (en) 2013-06-26
ES2426023T3 (es) 2013-10-18
WO2010083141A1 (en) 2010-07-22
JP2012515205A (ja) 2012-07-05
JP5638007B2 (ja) 2014-12-10
AR075139A1 (es) 2011-03-09
EP2379553A1 (en) 2011-10-26
US20110015175A1 (en) 2011-01-20
US8349880B2 (en) 2013-01-08
CN102356081A (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
CN102356081B (zh) 减少β-淀粉状蛋白生成的双环化合物
JP7453989B2 (ja) 抗癌剤として有用な縮合三環式化合物
JP6712344B2 (ja) Betタンパク質阻害剤としての三環式複素環
JP5666304B2 (ja) 新規な縮合アミノジヒドロチアジン誘導体
CN102971325B (zh) 用于减少β-淀粉样蛋白产生的化合物
US9079914B2 (en) Fused aminodihydro-oxazine derivatives
CN112770745B (zh) 用于治疗特定白血病的化合物
KR101428346B1 (ko) 벤즈옥사제핀 pi3k 억제 화합물 및 사용 방법
CN108558871B (zh) 作为抗癌剂的三环化合物
JP2019206584A (ja) BETタンパク質阻害剤としての1H−ピロロ[2,3−c]ピリジン−7(6H)−オン及びピラゾロ[3,4−c]ピリジン−7(6H)−オン
CN114072393A (zh) 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物
TW201107311A (en) Compounds for the reduction of β-amyloid production
CN101815713A (zh) 多环化合物
TW201441233A (zh) 作爲β-分泌酶抑制劑之稠合多環的碸化合物及其使用方法
HK40129049A (zh) 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物
TW202545520A (zh) 化合物及其醫藥用途
HK40123924A (zh) 作为qpctl和qpct抑制剂用於治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1,2,4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物
CN116640156A (zh) Ripk1抑制剂
HK40052099A (en) Compounds for treating certain leukemias
HK40052099B (en) Compounds for treating certain leukemias

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140827

Termination date: 20170112